secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001558370-23-008953
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Protalix/Chiesi's ELFABRIO for Fabry disease in adults
-------------------------------------------------------------------

- FDA approved ELFABRIO (pegunigalsidase alfa-iwxj) for adult Fabry disease patients.
- ELFABRIO is a PEGylated enzyme replacement therapy with a half-life of 78.9 ± 10.3 hours.
- More than 140 patients studied; head-to-head trial showed non-inferior efficacy to agalsidase beta in controlling eGFR decline.
- Most common adverse reactions (≥15%): infusion reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, sinusitis.
- Protalix CEO says approval is a testament to team dedication; Chiesi offers alternative treatment option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023008953/0001558370-23-008953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023008953/plx-20230510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer